WALTHAM, Mass., May 30, 2018 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced that
members of the management team will participate in two upcoming
investor conferences. The details for the two conferences are:
- Jefferies 2018 Global Healthcare Conference in New York on Wednesday,
June 6, 2018. Corporate presentation at 4:30 pm ET.
- JMP Securities Life Sciences Conference at the St. Regis New
York on Wednesday, June 20, 2018.
Panel discussion at 3:30 pm ET.
A live webcast of the Jefferies 2018 Global Healthcare
Conference presentation can be accessed from the Investor section
of the Company's website at www.syndax.com, where a replay of the
events will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company is developing its lead product candidate, entinostat, a
once-weekly, oral, small molecule, class I HDAC inhibitor, in
combination with exemestane and several approved PD-1/PD-L1
antagonists. The Company's pipeline also includes SNDX-6352, a
monoclonal antibody that blocks the colony stimulating factor 1
(CSF-1) receptor, as well as a portfolio of potent and selective
inhibitors targeting the binding interaction of Menin with MLLr.
For more information, please visit www.syndax.com or follow the
Company on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-participation-at-two-upcoming-investor-conferences-300656144.html
SOURCE Syndax Pharmaceuticals